✦ LIBER ✦

Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer

✍ Scribed by Hennessy, B. T. J.; Timms, K. M.; Carey, M. S.; Gutin, A.; Meyer, L. A.; Flake, D. D.; Abkevich, V.; Potter, J.; Pruss, D.; Glenn, P.; Li, Y.; Li, J.; Gonzalez-Angulo, A. M.; McCune, K. S.; Markman, M.; Broaddus, R. R.; Lanchbury, J. S.; Lu, K. H.; Mills, G. B.

Book ID: 124056034
Publisher: American Society of Clinical Oncology
Year: 2010
Tongue: English
Weight: 182 KB
Volume: 28
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2009.27.2997

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Oral poly(ADP-ribose) polymerase inhibit

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

✍ M William Audeh; James Carmichael; Richard T Penson; Michael Friedlander; Bethan 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 268 KB

Oral poly(ADP-ribose) polymerase inhibit

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

✍ Andrew Tutt; Mark Robson; Judy E Garber; Susan M Domchek; M William Audeh; Jeffr 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 594 KB

Oral poly(ADP-ribose) polymerase inhibit

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

✍ Gelmon, K.A. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 107 KB

The poly(ADP-ribose) polymerase inhibito

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

✍ Sandhu, Shahneen K; Schelman, William R; Wilding, George; Moreno, Victor; Baird, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 435 KB

Phase II, Open-Label, Randomized, Multic

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

✍ Kaye, S. B.; Lubinski, J.; Matulonis, U.; Ang, J. E.; Gourley, C.; Karlan, B. Y. 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 165 KB

Promoter hypomethylation, especially aro

Promoter hypomethylation, especially around the E26 transformation-specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer

✍ Fang-Fang Bi, Da Li, Qing Yang 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 224 KB